PACE-CME

The safety of PCSK9 inhibitors - how low can we go?

The safety of PCSK inhibitors  how low can we go
RestartResume
5' education - Jan. 22, 2020 - Robert Giugliano, MD
  • Overview

    Robert Giugliano explains that very low LDL-c levels are safe, using data of recent clinical trials with LDL-c lowering drugs.

  • Educational information

    This video was recorded as part of the two-day meeting 'Current Challenges in Lipid Management and Cardiovascular Risk Reduction' at Brigham and Women's Hospital/Harvard Medical School in Boston, MA, USA on October 31 2019.

  • Faculty

    Robert Giugliano, MD is cardiologist in the Brigham and Women's Hospital, Associate Prof at Harvard Medical School and investigator of the TIMI Study group in Boston, MA, USA.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free